Thank you for that clarification.
The reason I referred to the investment in performance review times is that we had developed a backlog in product reviews. The bottom line for us is that we never allow a product on the market without doing a thorough review. That's why a backlog was created. That's why the investment was made--so we had more capacity and stronger management systems to oversee this review process. So whenever we approve a product, we are confident that it meets the tests of the Food and Drugs Act for safety, efficacy, and quality, absolutely.